Comparative Effects of Platelet-Rich Plasma (PRP) and Erythropoietin (EPO) on Hematological and Cytological Indices of Bone Marrow in Diabetic Rats

Jalali, Seyedeh Missagh; Jamshidian, Javad; Lak, Reza

doi:10.48307/FMSJ.2025.29.3.257

[Home ] [Archive]

[ فارسی ]

Main Menu

Home

Journal Information

Indexing Sources

Guide for Authors

Online Submission

Ethics

Articles archive

For Reviewers

Contact us

Basic and Clinical Biochemistry and Nutrition

DOAJ

CINAHL

EBSCO

IMEMR

ISC

Search in website

Receive site information

enamad

Volume 29, Issue 3 (Bimonthly 2025)

Feyz Med Sci J 2025, 29(3): 257-265

Back to browse issues page

Comparative Effects of Platelet-Rich Plasma (PRP) and Erythropoietin (EPO) on Hematological and Cytological Indices of Bone Marrow in Diabetic Rats

Seyedeh Missagh Jalali ^*

, Javad Jamshidian

, Reza Lak

Department of Clinical Sciences, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz, Iran , mi.jalali@scu.ac.ir

Abstract: (316 Views)

Background and Aim: Diabetes, a chronic metabolic disorder with increasing prevalence, exerts detrimental effects on the hematological system and bone marrow. Given the growth-stimulating and tissue-repair properties of platelet-rich plasma (PRP) and erythropoietin (EPO), this study aimed to compare their effects on hematological and cytological indices of bone marrow in diabetic rats.
Methods: In this experimental study, 30 male Wistar rats were divided into five groups: control, diabetic, diabetic treated with PRP, diabetic treated with EPO, and diabetic treated with a combination of PRP and EPO. Diabetes was induced via streptozotocin injection. PRP (0.5 mL/kg, twice weekly) and EPO (300 U/kg, three times weekly) were administered subcutaneously for four weeks. At the end of the treatment period, blood and bone marrow samples were collected, and hematological and cytological indices were assessed.
Results: Diabetes significantly reduced red blood cell count, hemoglobin, hematocrit, and leukocyte levels in both blood and bone marrow (P<0.05). Mean corpuscular volume (MCV) was significantly increased in all diabetic groups compared to the control group (P<0.05). In the EPO-treated diabetic group, red blood cell count, hemoglobin, and hematocrit were significantly increased compared to the untreated diabetic group (P<0.05). Cytological analysis of bone marrow revealed a slight reduction in mature myeloid and lymphoid cell populations in the diabetic group compared to the control group, while a non-significant increase in these cells was observed in the diabetic groups treated with PRP, EPO, or their combination (P<0.05).
Conclusion: The findings suggest that PRP likely mitigates red blood cell damage by reducing oxidative and inflammatory stress, while EPO counteracts the deleterious effects of diabetes by enhancing erythropoiesis and reducing inflammation. The combined PRP and EPO treatment may further attenuate diabetes-induced damage to the hematological system and bone marrow through synergistic effects. However, further studies are needed to elucidate the precise mechanisms underlying these effects and their potential clinical applications in diabetes management.

Keywords: Diabetes, Platelet-Rich Plasma (PRP), Erythropoietin (EPO), Hematology, Bone Marrow

Full-Text [PDF 418 kb] (34 Downloads)

Type of Study: Research | Subject: medicine, paraclinic
Received: 2025/04/20 | Revised: 2025/08/20 | Accepted: 2025/07/8 | Published: 2025/08/17

References

1. Unnikrishnan R, Anjana RM, Mohan V. Diabetes mellitus and its complications in India. Nat Rev Endocrinol. 2016; 12(6): 357-70. doi:10.1038/nrendo.2016.53 PMid:27080137

2. Zimmet P, Alberti K, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001; 414 (6865):782-7. doi:10.1038/414782a PMid:11742409

3. Thomas NJ, Walkey HC, Kaur A, Misra S, Oliver NS, Colclough K, et al. The relationship between islet autoantibody status and the genetic risk of type 1 diabetes in adult-onset type 1 diabetes. Diabetologia. 2023; 66 (2): 310-20. doi:10.1007/s00125-022-05823-1 PMid:36355183 PMCid:PMC9807542

4. Tomita T. Apoptosis of pancreatic β-cells in Type 1 diabetes. Bosn J Basic Med Sci. 2017;17(3):183-93. doi:10.17305/bjbms.2017.1961 PMid:28368239 PMCid:PMC5581966

5. Aguayo-Mazzucato C, Diaque P, Hernandez S, Rosas S, Kostic A, Caballero AE, et al. Understanding the growing epidemic of type 2 diabetes in the Hispanic population living in the United States. Diabetes Metab Res Rev. 2019; 35(2):e3097. doi:10.1002/dmrr.3097 PMid:30445663 PMCid:PMC6953173

6. Chidhambara PD, Raj DS, Kumar VP, Sankaran U. Experimental animal models for diabetes and its related complications-a review. Lab Anim Res. 2021;37:127-40. doi:10.1186/s42826-021-00101-4 PMid:34429169 PMCid:PMC8385906

7. Fadini GP, Ferraro F, Quaini F, Asahara T, Madeddu P. Concise review: diabetes, the bone marrow niche, and impaired vascular regeneration. Stem Cells Transl Med. 2014; 3(8):949-57. doi:10.5966/sctm.2013-0195 PMid:24646489 PMCid:PMC4006490

8. Kim TY, Schafer AL. Diabetes and bone marrow adiposity. Curr Osteoporos Rep. 2016;14(6):337-44. doi:10.1007/s11914-016-0336-x PMid:27714580 PMCid:PMC5126977

9. Stookey J, Burg M, Sellmeyer DE, Greenleaf JE, Arieff A, Van Hove L, Gardner C, King JC. A proposed method for assessing plasma hypertonicity in vivo. Eur J Clin Nutr. 2007; 61(1): 143-6. doi:10.1038/sj.ejcn.1602484 PMid:16835598

10. Collister D, Rigatto C, Tangri N. Anemia management in chronic kidney disease and dialysis: a narrative review. Curr Opin Nephrol Hypertens. 2017; 26(3): 214-8. doi:10.1097/MNH.0000000000000317 PMid:28306566

11. Nekoui A, Blaise G. Erythropoietin and nonhematopoietic effects. Am J Med Sci. 2017; 353 (1): 76-81. doi:10.1016/j.amjms.2016.10.009 PMid:28104107

12. McGill JB, Bell DS. Anemia and the role of erythropoietin in diabetes. J Diabetes Complicat. 2006; 20 (4): 262-72. doi:10.1016/j.jdiacomp.2005.07.005 PMid:16798472

13. Suresh S, Alvarez JC, Dey S, Noguchi CT. Erythropoietin-induced changes in bone and bone marrow in mouse models of diet-induced obesity. Int J Mol Sci. 2020;21(5):1657. doi:10.3390/ijms21051657 PMid:32121294 PMCid:PMC7084787

14. Samy A, El-Adl M, Rezk S, Marghani B, Eldomany W, Eldesoky A, et al. The potential protective and therapeutic effects of platelet-rich plasma on ischemia/reperfusion injury following experimental torsion/detorsion of testis in the Albino rat model. Life Sci. 2020;256:117982. doi:10.1016/j.lfs.2020.117982 PMid:32562693

15. Alves R, Grimalt R. A review of platelet-rich plasma: history, biology, mechanism of action, and classification. Skin Appendage Disord. 2018; 4(1): 18-24. doi:10.1159/000477353 PMid:29457008 PMCid:PMC5806188

16. Ehrenfest DMD, Andia I, Zumstein MA, Zhang CQ, Pinto NR, Bielecki T, et al. Classification of platelet concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: current consensus, clinical implications and perspectives. Muscles Ligaments Tendons J. 2014;4(1):3-9. doi: 10.11138/mltj/2014.4.1.003

17. El-Tahawy NF, Rifaai RA, Saber EA, Saied SR, Ibrahim RA. Effect of platelet-rich plasma (PRP) injection on the endocrine pancreas of the experimentally induced diabetes in male albino rats: a histological and immunohistochemical study. J Diabetes Metab. 2017;8 (730): 2. doi:10.4172/2155-6156.1000730

18. Hafez SMNA, Zenhom NM, Abdel-Hamid HA. Effects of platelet-rich plasma on experimentally induced diabetic heart injury. Int Immunopharmacol. 2021; 96: 107814. doi:10.1016/j.intimp.2021.107814 PMid:34162165

19. Wang-Fischer Y, Garyantes T. Improving the reliability and utility of streptozotocin-induced rat diabetic model. J Diabetes Res. 2018;2018:8054073. doi:10.1155/2018/8054073 PMid:30345315 PMCid:PMC6174751

20. Zarin M, Karbalaei N, Keshtgar S, Nemati M. Platelet-rich plasma improves impaired glucose hemostasis, disrupted insulin secretion, and pancreatic oxidative stress in streptozotocin-induced diabetic rat. Growth Factors. 2019; 37(5-6):226-37. doi:10.1080/08977194.2020.1735382 PMid:32151173

21. Mazzanti L, et al. Diabetes mellitus induces red blood cell plasma membrane alterations possibly affecting the aging process. Clin Biochem. 1992; 25(1):41-6. doi:10.1016/0009-9120(92)80044-H PMid:1312917

22. Chang HY, Li X, Karniadakis GE. Modeling of biomechanics and biorheology of red blood cells in type 2 diabetes mellitus. Biophys J. 2017;113(2):481-90. doi:10.1016/j.bpj.2017.06.014 PMid:28746857 PMCid:PMC5529610

23. Zaki MK, Abed MN, Alassaf FA. The regulatory role of erythropoietin in diabetes mellitus: a focus on oxidative and glycemic statuses. Rom J Med Pract. 2024;19(2):1-6. doi:10.37897/RJMP.2024.2.6

24. Lian Z, Yin X, Li H, Jia L, He X, Yan Y, et al. Synergistic effect of bone marrow-derived mesenchymal stem cells and platelet-rich plasma in streptozotocin-induced diabetic rats. Ann Dermatol. 2014; 26(1):1-10. doi:10.5021/ad.2014.26.1.1 PMid:24648680 PMCid:PMC3956772

25. Graves DT, Liu R, Alikhani M, Al-Mashat H, Trackman PC. Diabetes-enhanced inflammation and apoptosis-impact on periodontal pathology. J Dent Res. 2006;85(1):15-21. doi:10.1177/154405910608500103 PMid:16373675

26. Peng B, Kong G, Yang C, Ming Y. Erythropoietin and its derivatives: from tissue protection to immune regulation. Cell Death Dis. 2020;11(2):79. doi:10.1038/s41419-020-2276-8 PMid:32015330 PMCid:PMC6997384

27. Bakadia BM, Ahmed AAQ, Lamboni L, Shi Z, Mukole BM, Zheng R, et al. Engineering homologous platelet-rich plasma, platelet-rich plasma-derived exosomes, and mesenchymal stem cell-derived exosomes-based dual-crosslinked hydrogels as bioactive diabetic wound dressings. Bioact Mater. 2023; 28: 74-94. doi:10.1016/j.bioactmat.2023.05.002 PMid:37234363 PMCid:PMC10206161

28. OuYang H, Tang Y, Yang F, Ren X, Yang J, Cao H, et al. Platelet-rich plasma for the treatment of diabetic foot ulcer: a systematic review. Front Endocrinol. 2023;14: 1256081. doi:10.3389/fendo.2023.1256081 PMid:38169990 PMCid:PMC10760804

29. Antoniadou C, Gavriilidis E, Ritis K, Tsilingiris D. Anemia in Diabetes Mellitus: pathogenetic aspects and the value of early erythropoietin therapy. Metab Open. 2025; 100344. doi:10.1016/j.metop.2024.100344 PMid:39886103 PMCid:PMC11780985

Send email to the article author

Add your comments about this article

‎ 10.48307/FMSJ.2025.29.3.257

Mendeley

Zotero

RefWorks

Jalali S M, Jamshidian J, Lak R. Comparative Effects of Platelet-Rich Plasma (PRP) and Erythropoietin (EPO) on Hematological and Cytological Indices of Bone Marrow in Diabetic Rats. Feyz Med Sci J 2025; 29 (3) :257-265
URL: http://feyz.kaums.ac.ir/article-1-5330-en.html

This open access journal is licensed under a Creative Commons Attribution-NonCommercial ۴.۰ International License. CC BY-NC ۴. Design and publishing by Kashan University of Medical Sciences.
Copyright ۲۰۲۳© Feyz Medical Sciences Journal. All rights reserved.

Volume 29, Issue 3 (Bimonthly 2025)

Back to browse issues page

Persian site map - English site map - Created in 0.05 seconds with 44 queries by YEKTAWEB 4714